Recent developments following Marty Makary's resignation as FDA commissioner have elevated Kyle Diamantas to acting commissioner, positioning him as the leading candidate in trader assessments for the permanent role. Diamantas, previously deputy commissioner for food with prior legal experience in regulatory matters, received the acting appointment directly from President Trump amid efforts to advance administration priorities on food safety and agency operations. Health and Human Services officials are actively narrowing candidates for nomination, with plans to recommend a permanent selection to Trump in the coming weeks for Senate confirmation. Other names under discussion, including former commissioner Stephen Hahn and Brett Giroir, reflect consideration of veterans from prior administrations, though the current interim leadership and timeline favor Diamantas in current consensus pricing.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоKyle Diamantas 67%
Stephen Hahn 7%
Brett Giroir 3.9%
Sara Brenner 3.3%
НОВЕ
НОВЕ
Dec 31, 2026
Kyle Diamantas
52%
Stephen Hahn
7%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
1%
Kyle Diamantas 67%
Stephen Hahn 7%
Brett Giroir 3.9%
Sara Brenner 3.3%
НОВЕ
НОВЕ
Dec 31, 2026
Kyle Diamantas
$1,515 Обс.
52%
Stephen Hahn
$975 Обс.
7%
Brett Giroir
$1,510 Обс.
4%
Grace Graham
$1,842 Обс.
3%
Sara Brenner
$848 Обс.
3%
No announcement by December 31
$425 Обс.
1%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent developments following Marty Makary's resignation as FDA commissioner have elevated Kyle Diamantas to acting commissioner, positioning him as the leading candidate in trader assessments for the permanent role. Diamantas, previously deputy commissioner for food with prior legal experience in regulatory matters, received the acting appointment directly from President Trump amid efforts to advance administration priorities on food safety and agency operations. Health and Human Services officials are actively narrowing candidates for nomination, with plans to recommend a permanent selection to Trump in the coming weeks for Senate confirmation. Other names under discussion, including former commissioner Stephen Hahn and Brett Giroir, reflect consideration of veterans from prior administrations, though the current interim leadership and timeline favor Diamantas in current consensus pricing.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Ринок відкрито: May 12, 2026, 7:59 PM ET
Обсяг
$7,115Дата завершення
Dec 31, 2026Ринок відкрито
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent developments following Marty Makary's resignation as FDA commissioner have elevated Kyle Diamantas to acting commissioner, positioning him as the leading candidate in trader assessments for the permanent role. Diamantas, previously deputy commissioner for food with prior legal experience in regulatory matters, received the acting appointment directly from President Trump amid efforts to advance administration priorities on food safety and agency operations. Health and Human Services officials are actively narrowing candidates for nomination, with plans to recommend a permanent selection to Trump in the coming weeks for Senate confirmation. Other names under discussion, including former commissioner Stephen Hahn and Brett Giroir, reflect consideration of veterans from prior administrations, though the current interim leadership and timeline favor Diamantas in current consensus pricing.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Обсяг
$7,115Дата завершення
Dec 31, 2026Ринок відкрито
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Recent developments following Marty Makary's resignation as FDA commissioner have elevated Kyle Diamantas to acting commissioner, positioning him as the leading candidate in trader assessments for the permanent role. Diamantas, previously deputy commissioner for food with prior legal experience in regulatory matters, received the acting appointment directly from President Trump amid efforts to advance administration priorities on food safety and agency operations. Health and Human Services officials are actively narrowing candidates for nomination, with plans to recommend a permanent selection to Trump in the coming weeks for Senate confirmation. Other names under discussion, including former commissioner Stephen Hahn and Brett Giroir, reflect consideration of veterans from prior administrations, though the current interim leadership and timeline favor Diamantas in current consensus pricing.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання